ArticleNaunyn-Schmiedeberg's archives of pharmacology2019
In vitro study of the cytotoxicity of thymoquinone/curcumin fluorescent liposomes.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Advancements in Liposomal Nanomedicines: Innovative Formulations, Therapeutic Applications, and Future Directions in Precision Medicine.International journal of nanomedicine · 2025Review
- Natural compounds-based nanomedicines for cancer treatment: Future directions and challenges.Drug delivery and translational research · 2024Review
- Antinociceptive Action of Thymoquinone-Loaded Liposomes in an In Vivo Model of Tendinopathy.Pharmaceutics · 2023Article
- Curcumin, thymoquinone, and 3, 3'-diindolylmethane combinations attenuate lung and liver cancers progression.Frontiers in pharmacology · 2022Article
- Identification of the Signature Genes and Network of Reactive Oxygen Species Related Genes and DNA Repair Genes in Lung Adenocarcinoma.Frontiers in medicine · 2022Article
- Reserpine-induced altered neuro-behavioral, biochemical and histopathological assessments prevent by enhanced antioxidant defence system of thymoquinone in mice.Metabolic brain disease · 2021Article
- Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, thymoquinone-loaded liposomes (Lip (TQ)), curcumin-encapsulated liposome (Lip (CUR)), and thymoquinone/curcumin-encapsulated liposome (Lip (TQ + CUR)) in addition to rhodamine-labeled thymoquinone/curcumin liposome (Lip (TQ + CUR + ROD)) were prepared with encapsulation efficiency exceeding 99%. The aim of the present study was to evaluate the effect of the different prepared formulations either labeled with the fluorescent dye (rhodamine B) or not on A549 lung cancer cells. Cytotoxicity of different formulations was assessed by MTT assay. Proliferation of A549 cells was significantly inhibited by the different formulations in a concentration-dependent manner in 72 h. The Lip (TQ + CUR + ROD) formulation demonstrated the lowest IC
Indexed as
Identifiers
31377882What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.